Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Duality Biotherapeutics's Days Inventory or its related term are showing as below:
HKSE:09606's Days Inventory is not ranked *
in the Biotechnology industry.
Industry Median: 184.675 * Ranked among companies with meaningful Days Inventory only.
Duality Biotherapeutics's Days Inventory
stayed the same
from Jun. 2025 (0.00) to Jun. 2026 (0.00).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Duality Biotherapeutics's Inventory-to-Revenue for the
six
months ended in Jun. 2026 was 0.00.
Duality Biotherapeutics (HKSE:09606) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Duality Biotherapeutics's Inventory Turnover for the
six
months ended in Jun. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Duality Biotherapeutics's Inventory to Revenue for the
six
months ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Duality Biotherapeutics Days Inventory Related Terms
Duality Biotherapeutics Days Inventory Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Duality Biotherapeutics Days Inventory Chart
Duality Biotherapeutics Annual Data
Trend
Dec22
Dec23
Dec24
Dec25
Days Inventory
0.00
0.00
0.00
0.00
Duality Biotherapeutics Semi-Annual Data
Jun25
Dec25
Jun26
Days Inventory
0.00
0.00
0.00
HKSE:09606 vs VRTX, REGN, MRNA: Days Inventory Comparison
For the Biotechnology subindustry, Duality Biotherapeutics's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Duality Biotherapeutics Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Duality Biotherapeutics's Days Inventory distribution charts can be found below:
* The bar in red indicates where Duality Biotherapeutics's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Duality Biotherapeutics (HKSE:09606) has a Days Inventory of 0.00 as of Jun. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Duality Biotherapeutics and its competitors. According to the industry distribution chart, Duality Biotherapeutics ranks #999999 out of 638 companies in the Biotechnology industry.
Is Duality Biotherapeutics' Days Inventory too high?
Duality Biotherapeutics' current Days Inventory is 0.00. Based on the distribution chart, Duality Biotherapeutics ranks #999999 out of 638 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Duality Biotherapeutics has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Duality Biotherapeutics' Days Inventory compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Duality Biotherapeutics ranks #999999 out of 638 companies for Days Inventory. This places Duality Biotherapeutics in the lower half of its industry. The industry median Days Inventory is 184.68. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 184.68, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Duality Biotherapeutics and its competitors. For the Biotechnology industry, the median Days Inventory is 184.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Duality Biotherapeutics's current Days Inventory is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Duality Biotherapeutics stock overvalued right now?
Duality Biotherapeutics (HKSE:09606) has a current Days Inventory of 0.00. The current Days Inventory is 0.00. Duality Biotherapeutics' overall GF Score™ is 9/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Duality Biotherapeutics (HKSE:09606), the current Days Inventory is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Duality Biotherapeutics Inc is engaged in the discovery and development of antibody-drug conjugate (ADC) therapeutics, focusing on treatments for cancer and other diseases. The company has a diversified pipeline of ADC candidates, including two core products: DB-1303/BNT323, a HER2-targeting ADC for cancers such as breast and endometrial cancer, and DB-1311/BNT324, a B7-H3-targeting ADC for multiple solid tumors. In addition, it has several other clinical-stage ADC candidates with therapeutic potential, as well as multiple preclinical ADCs, including candidates expected to enter clinical trials. Its key products, including DB-1303/BNT323, DB-1311/BNT324, and DB-1305/BNT325, have received Fast Track Designation, with DB-1303 being a late-stage candidate undergoing registrational studies.
9GF Score
Get the complete analysis for HKSE:09606
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:09606 has been successfully added to your 
